Found: 7
Select item for more details and to access through your institution.
CD5 deletion enhances the antitumor activity of adoptive T cell therapies.
- Published in:
- Science Immunology, 2024, v. 9, n. 97, p. 1, doi. 10.1126/sciimmunol.adn6509
- By:
- Publication type:
- Article
Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel.
- Published in:
- Journal of Hematology & Oncology, 2024, v. 17, n. 1, p. 1, doi. 10.1186/s13045-024-01542-9
- By:
- Publication type:
- Article
Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study.
- Published in:
- Molecular Cancer, 2023, v. 22, n. 1, p. 1, doi. 10.1186/s12943-023-01886-9
- By:
- Publication type:
- Article
Anti-PD-L1 monoclonal antibody for the management of chronic disseminated intravascular coagulation secondary to a urothelial carcinoma: a case report.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study †.
- Published in:
- Cancers, 2022, v. 14, n. 4, p. 1018, doi. 10.3390/cancers14041018
- By:
- Publication type:
- Article
CAR‐T TREK through the lymphoma universe, to boldly go where no other therapy has gone before.
- Published in:
- British Journal of Haematology, 2021, v. 193, n. 3, p. 449, doi. 10.1111/bjh.17191
- By:
- Publication type:
- Article
Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden.
- Published in:
- 2019
- By:
- Publication type:
- Journal Article